Little Rock, ARKANSAS19 Active Studies

Atopic Dermatitis Clinical Trials in Little Rock, ARKANSAS

Find 19 actively recruiting atopic dermatitis clinical trials in Little Rock, ARKANSAS. Connect with local research sites and explore new treatment options.

19
Active Trials
14
Sponsors
9,180
Enrolling

Recruiting Atopic Dermatitis Studies in Little Rock

RecruitingLittle Rock, ARKANSASNCT05050162

Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

This phase II/III trial compares whether cisplatin given weekly with radiation therapy is better tolerated than cisplatin given every three weeks with radiation therapy for the treatment of head and n...

1,714 participants
NRG Oncology
View Study Details
RecruitingLittle Rock, ARKANSASNCT06225596

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

This is a global, multicenter, randomized, open-label study, with an adaptive design. The main objective of the study is to measure the efficacy and safety of BT8009 (zelenectide pevedotin) as monothe...

956 participants
BicycleTx Limited
View Study Details
RecruitingLittle Rock, ARKANSASNCT05538663

Intravesical BCG vs GEMDOCE in NMIBC

The study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will result in a non-inferior event-free survival...

870 participants
ECOG-ACRIN Cancer Research Group
View Study Details
RecruitingLittle Rock, ARKANSASNCT06461897

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin may not be enough to control the AD in trial parti...

675 participants
AbbVie
View Study Details
RecruitingLittle Rock, ARKANSASNCT01810913

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage I...

613 participants
National Cancer Institute (NCI)
View Study Details
RecruitingLittle Rock, ARKANSASNCT02339571

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melan...

600 participants
National Cancer Institute (NCI)
View Study Details
RecruitingLittle Rock, ARKANSASNCT02138734

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

This is a Phase Ib/IIb, randomized, two-cohort, open-label, multicenter study of intravesical N-803 plus BCG versus BCG alone, in BCG naïve patients with high-grade NMIBC....

596 participants
ImmunityBio, Inc.
View Study Details
RecruitingLittle Rock, ARKANSASNCT06319820

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of ...

560 participants
Janssen Research & Development, LLC
View Study Details
RecruitingLittle Rock, ARKANSASNCT04752722

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phase...

350 participants
enGene, Inc.
View Study Details
RecruitingLittle Rock, ARKANSASNCT06567743

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer....

325 participants
CG Oncology, Inc.
View Study Details
RecruitingLittle Rock, ARKANSASNCT06973577

P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety

Primary: To evaluate the efficacy of CTN in adults ages with ADHD and comorbid anxiety (AISRS) Key Secondary: To assess the efficacy of CTN in adults ages with ADHD and comorbid anxiety...

308 participants
Otsuka Pharmaceutical Development & Commercialization, Inc.
View Study Details
RecruitingLittle Rock, ARKANSASNCT04781140

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD....

286 participants
Supernus Pharmaceuticals, Inc.
View Study Details
RecruitingLittle Rock, ARKANSASNCT03609216

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

This phase II trial studies how well gemcitabine hydrochloride and cisplatin work in treating participants with invasive bladder urothelial cancer. Drugs used in chemotherapy, such as gemcitabine hydr...

271 participants
Alliance for Clinical Trials in Oncology
View Study Details
RecruitingLittle Rock, ARKANSASNCT06211764

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) within 1 year of last dose...

250 participants
Janssen Research & Development, LLC
View Study Details
RecruitingLittle Rock, ARKANSASNCT04166409

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated lo...

220 participants
National Cancer Institute (NCI)
View Study Details
RecruitingLittle Rock, ARKANSASNCT04671667

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with...

188 participants
National Cancer Institute (NCI)
View Study Details
RecruitingLittle Rock, ARKANSASNCT06589804

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back afte...

158 participants
National Cancer Institute (NCI)
View Study Details
RecruitingLittle Rock, ARKANSASNCT05023486

NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

Multicenter, open-label study in patients with advanced or metastatic solid tumor malignancies to evaluate the safety, tolerability, and preliminary anti-tumor efficacy, PK, and pharmacodynamics of co...

140 participants
Novita Pharmaceuticals, Inc.
View Study Details
RecruitingLittle Rock, ARKANSASNCT05952934

Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence

This is a Phase II randomized, double-blind, placebo controlled, multi-site study of Candin. It is designed to show the efficacy and safety of a 7-dose regimen of Candin over a two-year period in term...

100 participants
University of Arkansas
View Study Details

About Atopic Dermatitis Clinical Trials in Little Rock

Atopic dermatitis (eczema) is a chronic inflammatory skin condition causing itchy, red, and dry skin. It is the most common form of eczema, often beginning in childhood. Treatment includes moisturizers, topical corticosteroids, immunomodulators, and newer biologics like dupilumab.

There are currently 19 atopic dermatitis clinical trials recruiting participants in Little Rock, ARKANSAS. These studies are seeking a combined 9,180 participants. Research is being sponsored by NRG Oncology, BicycleTx Limited, ECOG-ACRIN Cancer Research Group and 11 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Atopic Dermatitis Clinical Trials in Little Rock — FAQ

Are there atopic dermatitis clinical trials in Little Rock?

Yes, there are 19 atopic dermatitis clinical trials currently recruiting in Little Rock, ARKANSAS. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Little Rock?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Little Rock research site will contact you about next steps.

Are clinical trials in Little Rock free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Little Rock studies also compensate for your time and travel.

What atopic dermatitis treatments are being tested?

The 19 active trials in Little Rock are testing new therapies including novel drugs, biologics, and treatment approaches for atopic dermatitis.

Data updated March 2, 2026 from ClinicalTrials.gov